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Insulin resistanceependent risk factor for cardiovascular events and may contribute to cardio-
vascular disease. Low-grade chronic inﬂammation has been implicated in the pathogenesis of atherosclerosis.
We aimed at determining the impact of pathophysiologically high insulin concentrations on cytokine-
induced endothelial activation in human umbilical vein endothelial cells (HUVEC). HUVEC were incubated
with insulin (0–24 h)±tumor necrosis factor (TNF)-α or lipopolysaccharide (LPS). At pathophysiological/
pharmacological concentrations (10−9–10−7 mol/L), insulin selectively induced VCAM-1 expression and
potentiated the effects of TNF-α andLPS, effects reverted by the proteasome inhibitor lactacystin. Compared
with TNF-α alone, insulin+TNF-α doubled U937 cell adhesion. Insulin markedly increased TNF-α-induced
NF-κB activation and induced phosphorylated IκB-α accumulation. Therefore, hyperinsulinemia enhances
cytokine-induced VCAM-1 expression in endothelial cells, thus potentially contributing to detrimental effects
of other inﬂammatory stimuli on atherogenesis.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Increased circulating levels of pro-inﬂammatory cytokines, such as
interleukin(IL)-6 [1] and tumor necrosis factor (TNF)-α [2], as well as
high levels of acute phase reactants [3], have been found inpatientswith
insulin resistance, obesity and type 2 diabetes. Low-grade chronic
inﬂammationmay play a role in the pathogenesis of insulin resistance in
obesity and type 2 diabetes. Indeed, inﬂammatory cytokines inhibit
insulin signaling by impairing the tyrosine kinase activity of both the
insulin receptor (IR) and insulin receptor substrate (IRS)-1, thus acting as
mediators of insulin resistance [4,5]. Furthermore, mice lacking TNF
receptor function have been shown to develop protection from obesity-
induced insulin resistance [6]. Insulin resistance and compensatory
hyperinsulinemia are probably causally associated with elevated levels
of inﬂammatory markers and increased risk of cardiovascular disease
[7]. Thus, by determining insulin resistance, systemic low-grade chronic
inﬂammation would act as a key pathogenetic factor for cardiovascular
disease in type 2 diabetes and the metabolic syndrome [8].'Annunzio” University – Chieti,
eti, Italy. Tel.: +39 0871 41512;
l rights reserved.A growing body of evidence now suggests the existence of a bidi-
rectional relationship between hyperinsulinemia and low-grade
chronic inﬂammation, by which hyperinsulinemia might contribute
to vascular inﬂammation, and vascular inﬂammation leads to insulin
resistance and consequent compensatory hyperinsulinemia. Indeed,
in humans, plasma concentrations of the pro-inﬂammatory cytokines
IL-6 and TNF-α increase when insulin is administered together with
bacterial lipopolysaccharide (LPS) [9]. In human smooth muscle cells
[10], in murine glomerular vascular endothelial cells [11] and in
human adipose tissue [12] hyperinsulinemia exacerbates inﬂamma-
tion and increases levels of markers of oxidative stress, while on the
contrary insulin exerts prevailing anti-inﬂammatory effect at low,
physiological, concentrations [13–16]. Finally, in macrophages, insulin,
at pathophysiologically relevant concentrations, stimulates TNF-α
expression and production [17].
We have previously shown that in human umbilical endothelial cells
(HUVEC) insulin per se increases the expression of vascular cell adhesion
molecule-1 (VCAM-1) [18,19], probably the adhesion molecule most
relevant to the development of atherosclerosis [20]. However, the
impact of high insulin on the inﬂammatory response to cytokines is still
poorly characterized. In this studywe therefore investigated (a)whether
insulin promotes endothelial activation in human endothelial cells
exposed to pro-inﬂammatory cytokines; (b) the relevance of nuclear
factor(NF)-κB in insulin-mediated signaling and (c) the functional con-
sequences of the selective modulation of insulin signaling on mono-
cytoid cell adhesion to endothelial cells.
512 R. Madonna et al. / Biochimica et Biophysica Acta 1782 (2008) 511–5162. Materials and methods
2.1. Materials
Human recombinant insulin was purchased from Novo-Nordisk
Farmaceutici S.p.A., Rome, Italy. TNF-α, endotoxin, polymixin B and
lactacystinwere purchased from Sigma, St. Louis, MO. Themonoclonal
antibodies against VCAM-1 (Ab E1/6), E-selectin (Ab H18/7), ICAM-1
(Ab Hu 5/3), and a constitutive and non-cytokine-inducible endothe-
lial antigen (Ab E1/1) were kindly provided by M.A. Gimbrone, Jr.,
Brigham and Women's Hospital, Boston, MA.
2.2. Cell cultures
HUVEC were harvested enzymatically from umbilical cords with
type-II collagenase at 0.1 mg/mL, and cultured as described [21]. Cell
viability after treatments was assessed by evaluating several para-
meters, including cell morphology at phase-contrast microscopy,
Trypan blue exclusion, determination of total proteins and of the
surface expression of a constitutive and non-cytokine-inducible endo-
thelial cell antigen (E1/1) [22].
2.3. Cell surface immunoassays
Assays of cell surface molecules were carried out by cell surface
enzyme immunoassays (EIA), using mouse anti-human monoclonal
antibodies against VCAM-1 (Ab E1/6), E-Selectin (Ab H18/7), inter-
cellular adhesionmolecule (ICAM)-1 (Ab HU5/3), or a constitutive and
non-cytokine-inducible endothelial cell antigen (E1/1) [22]. Details of
the EIA have been previously reported [22].
2.4. Flow cytometry
Flow cytometric analysis of adhesion molecule expression was
performed by incubating HUVEC with the mouse anti-human mono-
clonal antibody E1/6 against VCAM-1 for 60min at 4 °C. Afterwashing,
cells were exposed to goat anti-mouse F(ab′)2, labeled with ﬂuor-
esceine-isothiocyanate (Immunotech, Cremascoli, Milan, Italy) at 4 °C.
After further washing and ﬁxation in 1% formaldehyde, the cell sus-
pension was passed through a FACScan analyzer (Becton-Dickinson
Immunocytometry Systems, Mountain View, CA). Results were plotted
as intensity of ﬂuorescence (arbitrary units, on a logarithmic scale, on
the abscissa) vs cell number (on the ordinate, total cells counted:
5×103 for each condition).
2.5. Immunocytochemistry
Cells grown in 24-well plates (LabTek, Nalgene/Nunc, Naperville,
IL, USA) were ﬁxed with cold methanol and then blocked in phos-
phate-buffered saline (PBS)/3% fetal calf serum (FCS) for 30 min. Cells
were incubated overnight at 4 °C in PBS/3% FCS with the mouse anti-
human monoclonal antibody E1/6 against VCAM-1. After incubation
with the primary antibody, cells were washed in PBS/3% FCS,
incubated for 1 h with the anti-mouse biotinylated antibody (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), and further incubated with
EstrAvidin peroxidase (Sigma). Slides were washed, incubated with
diaminobenzidine in the dark for 30 min, dehydrated in xylene and
ethanol, mounted in balsam, and observed with an inverted
microscope.
2.6. Measurement of TNF-α release
HUVEC seeded into 24-well culture plates (5×105 cells/well) were
stimulatedwith insulin (10−9–10−7mol/L) for 24 hwith orwithout LPS
(0.1 ng/mL). TNF-α release in the supernatants was measured by an
enzyme-linked immunosorbent assay (ELISA), using a commercial kit(Bender MedSystems, Vienna, Austria) and following the manufac-
turer's protocols. A standard curve was prepared from seven TNF-α
dilutions. The lower limit of sensitivity was 7.8 pg/mL. The overall
inter-assay and intra-assay coefﬁcients of variationwere b10%. In each
well, residual cells that had been deprived of mediumwere lysed with
ice-cold RadioImmuno Precipitation Assay (RIPA) buffer, and total
cellular proteins were measured with a BCA assay (Pierce, Rockford,
IL). The TNF-α content in the medium was normalized to cell protein
values.
2.7. Immunoblotting
Total proteins were isolated from HUVEC in ice-cold RIPA buffer.
Nuclear proteins were puriﬁed as previously described [21]. Proteins
were separated under reducing conditions and electroblotted onto
polyvinylidene ﬂuoride membranes (Immobilon-P; Millipore, Bed-
ford, MA). After blocking, the membranes were incubated overnight
at 4 °C with primary antibodies against VCAM-1 (Santa Cruz
Biotechnologies, Santa Cruz, CA), and with primary antibodies
against the constitutive and Ser32-phosphorylated inhibitor IκB-α
(Santa Cruz Biotechnology). The blots were developed using a
SuperSignal West Pico Chemiluminescent Substrate kit (Pierce). The
intensity of each immunoreactive protein band was measured by
densitometry.
2.8. Adhesion assays
HUVEC grown at conﬂuence in 6-well plates were incubated with
1mL of 1×106 cells/mL U937 cell suspension (American Tissue Culture
Collection, Rockville, MD), under rotating conditions (63 rpm) at room
temperature. To test the VCAM-1-dependence of adhesion, some
monolayers were treated with the mouse anti-human monoclonal
antibody E1/6, directed against VCAM-1. After 10 min, non-adhering
cells were removed and monolayers were ﬁxed in 1% paraformalde-
hyde. The number of adhering cells was determined by counting 8
different high-power ﬁelds (h.p.f.) using an ocular grid and a 20×
objective (0.09 mm2/ﬁeld). Fields for counting adherent leukocytes
were randomly located at half-radius distance from the center of the
monolayers.
2.9. Northern analysis
Total RNA was isolated by a single extraction using an acid gua-
nidinium thiocyanate–phenol–chloroform method [23]. Details of
Northern analysis have been previously reported [21].
2.10. Electrophoretic mobility (gel) shift assay
Nuclear proteins from stimulated or unstimulated HUVEC were
puriﬁed as previously described [21]. Protein concentration was
determined by the Bio-Rad Laboratories Protein Assay (Bio-Rad Labo-
ratories Inc, Hercules, CA). The double-stranded synthetic oligo-
nucleotide NF-κB motif (5′-AGT TGA GGG GAC TTT CCC AGG C-3′ and
5′-CCT GGG AAA GTC CCC TCA ACT-3′) was labeled with [γ-32P]-ATP.
Binding reactions containing 10 μg of crude nuclear extract were
performed using the electrophoretic mobility gel shift assay core
system (Promega, Madison, WI) according to the manufacturer's
protocol.
2.11. Statistical analysis
Two-group comparisons were performed by the Student's t-test
for unpaired values. Comparisons of means of ≥3 groups were per-
formed by analysis of variance (ANOVA), and the existence of indi-
vidual differences, in case of signiﬁcant F values at ANOVA, was tested
by Scheffé's multiple contrasts. Comparisons of distribution of
Table 1
The co-induction of VCAM-1 expression by insulin and TNF-α at ﬂow cytometry
Treatment % Gated (a) Fluorescence intensity (b)
Untreated 1.07±0.05 5.11±1.53
Insulin 10−9 mol/L⁎ 2.08±0.7 9.22±2.18
Insulin 10−8 mol/L⁎ 4.22±1.2 15.6±3.2
TNF-α 1 ng/mL⁎ 20.27±4.2 115.8±11
Insulin 10−9 mol/L+TNF-α 1 ng/mL⁎⁎ 32.87±5.3 148.7±14.3
Insulin 10−8 mol/L+TNF-α 1 ng/mL⁎⁎ 38.97±8.3 154.5±18.1
Subconﬂuent serum-starved HUVECwere treatedwith TNF-α and/or insulin (10−9–10−8mol/L)
for 16 h. Cells were then immunostained for VCAM-1 or FITC-conjugated IgG isotype
control and submitted to ﬂow cytometry. Values (a) are mean±S.D. of % cells expressing
VCAM-1; values (b) are mean±S.D. of units of ﬂuorescence intensity. Results are
representative of three independent experiments. ⁎pb0.05 vs unstimulated control;
⁎⁎pb0.05 vs TNF-α.
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Kolgomorov–Smirnov statistics with the aid of the CellQuest™ soft-
ware package from Becton-Dickinson, 1997.
3. Results
3.1. Insulin, at pathophysiological concentrations, potentiates cytokine-
induced VCAM-1 expression in human umbilical endothelial cells
Insulin, in a concentration-dependentmanner,per se inducedVCAM-1
surface expression (Fig.1A and Table 1), but also potentiated the effects of
TNF-α and LPS. Quiescent endothelial cells co-incubated with pathophy-
siologically relevant concentrations of insulin (10−9–10−8 mol/L) and low
concentrations of TNF-α (0.1 ng/mL) had an average 3.9-fold increase in
VCAM-1 expression (pb0.001 vs untreated cells), which was greater than
the stimulation by insulin alone (2-fold) or TNF-α alone (2.4-fold,
⁎pb0.001 vs untreated cells) (Fig. 1A). In the absence of any cytotoxic
effect (Online Supplementary Figure), the addition of insulin to TNF-α-
treated cells produced amaximumof 1.4-fold increase in VCAM-1 surface
expression (⁎⁎pb0.05, insulin+TNF-α- vs TNF-α-treated cells). Similar at-
least-additive and concentration-dependent effects of insulin were
obtainedwhenahigher TNF-α concentration (1ng/mL)wasused (Fig.1B).
The co-stimulatory effect of insulin and TNF-α seen at cell surface EIA
was paralleled by an increase of the total cellular content of VCAM-1, as
assessed by immunoblotting (Fig. 1E). Consistently, ﬂow cytometry
demonstrated that HUVEC treated with insulin for 16 h showed not
only a signiﬁcant increase in mean ﬂuorescent intensity for VCAM-1
compared with untreated cells, but also an expression greater than that
obtained after co-incubation with TNF-α 1 ng/mL (Table 1). We also
observed an at-least-additive and concentration-dependent effect on
VCAM-1 expression by adding increasing concentrations of insulin (10−9–Fig. 1. Co-stimulatory effects of insulin and TNF-α or LPS on VCAM-1 surface expression in
withdrawal and reduction of serum (down to 2%) for 20 h, and then stimulated with insulin (
1 ng/mL (B) or LPS 0.1 ng/mL (C), added to the medium at the same time as insulin. VCAM-1
are the mean±S.D. from ﬁve experiments, each consisting of 8 replicates per condition. ⁎pb0
immunocytochemical analysis of the effect of insulin and TNF-α on the surface expression o
factor withdrawal and reduction of serum (down to 2%) for 20 h, and stimulated with insulin
as insulin. Immunocytochemistry with a non-immune IgG revealed no staining (not shown).
cellular proteins extracted from subconﬂuent serum-starved HUVEC stimulated with insul
representative of 3 separate experiments.10−8 mol/L) to low concentrations of LPS (0.1 ng/mL). The maximum
induction of VCAM-1 expression with insulin and LPS co-administration
was 2.3-fold vs basal untreated cells, whereas it was 1.7-fold vs LPS-
treated cells (#pb0.05), and 1.4-fold with LPS alone vs untreated cells
(⁎pb0.05) (Fig.1C). Immunocytochemistry on endothelial cellmonolayers
further conﬁrmed the effect of insulin+TNF-α on VCAM-1 surface
expression. (Fig. 1D). Since a robust co-stimulatory effect of insulin was
seen at a concentration of TNF-α of 1 ng/mL, further experiments were
performed with this concentration of TNF-α.
Rulingout possible cytolytic or cytostatic effects of TNF-α and LPS [24],
phase-contrast microscopy revealed no morphologic signs of injury to
human endothelial cells due to TNF-α (1 ng/mL, 24 h) in these expe-
riments in the presence or absence of insulin (10−9–10−8 mol/L, 24 h)
(Online Supplementary Figure). Similarly, LPS (0.1ng/mLgiven for 2424h)
or TNF-α (1 ng/mL given for 24 24 h) or insulin alone (10−9–10−8 mol/L
given for 24 24 h) did not reduce cell number or protein content ofendothelial cells. Subconﬂuent HUVEC were starved in 96-well plates by growth factor
10−10–10−8 mol/L) for 16 h (panels A–C) with or without TNF-α 0.1 ng/mL (A), or TNF-α
expression at EIA is expressed as percent of control in the absence of insulin, and values
.05 vs unstimulated control; ⁎⁎pb0.05 vs TNF-α, and # pb0.05 vs LPS. Panel D shows the
f VCAM-1 in endothelial cells. HUVEC were grown in 24-well plates, starved by growth
(10−9 to 10−8 mol/L) for 16 h. TNF-α 1 ng/mL was added to the medium at the same time
Scale bar=20 μm. Panel E, immunoblotting with an antibody against VCAM-1 of the total
in (10−9–10−8 mol/L) for 16 h, in the presence or absence of TNF-α 1 ng/mL. Blots are
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protein E1/1 (Online Supplementary Table).
To rule-out that endotoxin contamination contributed to the effect of
insulin on VCAM-1 expression, the LPS inactivator polymixin B sulfate
(PMBS) was added in a parallel set of experiments. PMBS completely
abrogated LPS-inducedVCAM-1expression, buthadnoeffect on insulin±
TNF-α-induced VCAM-1 expression (data not shown).
Inﬂammatory mediators such as interferon-γ and LPS are known
to increase the secretion of TNF-α from several cell types, including
macrophages [25], monocytes [26] and smooth muscle cells [27]. In
HUVEC, LPS has been demonstrated however not to induce TNF
secretion [26]. In macrophages, insulin by itself has been shown to
increase gene and protein expression of TNF-α [17]. To test whether
insulin – alone or in combination with LPS – induces TNF-α secretion
in HUVEC, which might account, in an autocrine manner, for the
potentiation by insulin of the effects of other agents, we measured
TNF-α protein mass by ELISA in the cell medium of HUVEC treated
with insulin (10−9–10−7 mol/L) in the presence or absence of LPS
(0.1 ng/mL). Treatment of HUVECwith insulin alone or in the presence
of LPS for 16 h did not end up in any detectable production of TNF-α
(TNF-α concentrations always below the detection limit of our assay
(7.8 pg/mL)).
3.2. Insulin, at pathophysiological concentrations, increases cytokine-
induced monocytoid cell adhesion to human umbilical endothelial cells
Because the induction of VCAM-1 on the endothelium is known to
support monocyte adhesion, we examined the functional conse-
quences of endothelial treatment with insulin in terms of monocytoidFig. 2. Effect of insulin and TNF-α onmonocytoid cell adhesion to endothelial cells and on en
treatment of HUVEC on the adhesion of U937 in a rotational adhesion assay. HUVECwere star
either left untreated (a) or treated with 10−8 mol/L insulin (b), 1 ng/mL TNF-α (d), or a combin
VCAM-1 monoclonal antibody E1/6; in f, HUVEC were incubated with 10−8 mol/L insulin+1 n
insulin alone (b) or in addition with TNF-α (e) is due to VCAM-1, since markedly suppressed
30 min before the assay (c and f). Photographs represent randomly chosen high-power ﬁ
experiments with similar design. Quantitative data of U937 cell adhesion to endothelial cells
unstimulated control; each point is the mean±S.D. of adhering cells from 3 experiments, ea
TNF-α 1 ng/mL; #pb0.05 vs insulin 10−8 mol/L; ⁎⁎⁎pb0.05 vs insulin+TNF-α. Panel B: The
Ethidium bromide-staining of total RNA; and b: Northern analysis of VCAM-1 mRNA in in
withdrawal and reduction of serum (down to 2%) for 20 h, then incubated with insulin (10−8 m
treatment with insulin is compared with control without insulin. The blots from TNF-α-untr
compared with the conditions of TNF-α treatment. The images are representative of 2 indep
pixels, and are proportional to VCAM-1 mRNA in comparisons of conditions with and witho(U937) adhesion to endothelial cells, using a rotational adhesion assay.
In agreement with data on VCAM-1 surface expression, treatment of
quiescent endothelial cells with insulin (10−8 mol/L) alone for 16 h
produced a 2.8-fold increase in U937 cell adhesion compared with
control, unstimulated endothelial cells (Fig. 2, panels A and C, condi-
tions a and b). Stimulation of endothelial cells with TNF-α (1 ng/mL)
substantially increased U937 cell adhesion, and this effect was further
potentiated by the addition of insulin (2-fold increase in U937 cell
adhesion compared with TNF-α alone, Fig. 2, panels A and C, con-
ditions d and e). This insulin- and cytokine-induced adhesion was
markedly suppressed (by about 70%) by a 30 min pre-treatment of
endothelial cells with the blocking anti-VCAM-1monoclonal antibody
E1/6, at saturating concentrations (Fig. 2, panels A and C, conditions c
and f).
3.3. Insulin, at pathophysiological concentrations, induces and co-
induces VCAM-1 mRNA at Northern analysis
We observed increasedmRNA levels in cells treated with 10−8 mol/L
insulin±TNF-α (1 ng/mL), consistent with the observed increase of
VCAM-1 protein expression (Fig. 2, panels B and D). In untreated cells,
VCAM-1 mRNA was not detectable, while in cells treated with insulin
alone substantial levels of mRNAwere detected (albeit, compared with
stimulations in the presence of TNF-α, with longer exposure times and a
double intensifying screen) (pb0.05). Compared with TNF-α alone, the
addition of insulin to TNF-α increased levels of VCAM-1 mRNA by 1.6-
fold (pb0.05), as determined by densitometry of Northern blots at 4–6 h
in two different experiments. Overall, these results indicate that in-
creased VCAM-1 surface levels after insulin±cytokine stimulationdothelial VCAM-1 steady-state mRNA levels. Panel A: The effects of insulin and/or TNF-α
ved by growth factor withdrawal and reduction of serum (down to 2%) for 20 h, and then
ation of both (e) for 16 h. In c, HUVEC were incubated with 10−8 mol/L insulin+the anti-
g/mL TNF-α+the anti-VCAM-1 monoclonal antibody E1/6. The increased adhesion with
in the presence of saturating concentrations of the blocking anti-VCAM-1 antibody for
elds at half-radius distance from the center of the well in one of the 3 comparative
are presented in panel C. Numbers of adhering U937 cells were expressed as percent of
ch consisting of 8 counts per condition. ⁎pb0.05 vs unstimulated control; ⁎⁎pb0.05 vs
effect of insulin and TNF-α on the expression of VCAM-1 mRNA in endothelial cells. a:
sulin- and TNF-α-treated and untreated HUVEC. Cells were starved by growth factor
ol/L), TNF-α (1 ng/mL) and a combination of both, for 6 h. The signal resulting from cell
eated cells were obtained with a longer exposure time and a double intensifying screen
endent experiments. Densitometric analyses are presented in panel D as optical density
ut insulin. ⁎pb0.01 vs control (no insulin, no TNF-α); #pb0.01 vs TNF-α alone.
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levels in control conditions and their presence after stimulation with
insulin alone indirectly argues for an induction of transcription.
3.4. Insulin, at pathophysiological concentrations, increases cytokine-
induced NF-κB activation and the phosphorylated form of IκB-α in the
cytosol of human umbilical endothelial cells
Insulin treatment markedly increased TNF-α-induced activation of
NF-κB (Fig. 3A, lanes 3 and 4). The speciﬁcity of the NF-κB DNA-
protein complex was veriﬁed by successful competition with
unlabeled (cold) NF-κB oligonucleotide and by the lack of any binding
reaction with a mutated oligonucleotide (not shown). In addition,
there was no signiﬁcant and speciﬁc binding with the unlabeled (cold)
oligonucleotide (Fig. 3, lane 5), or by omitting the nuclear protein
extracts or the oligonucleotide probe (not shown), as well as by using
nuclear protein extracts from unstimulated HUVEC (Fig. 3, lane 1).
Insulin treatment further increased TNF-α-induced cellular accumu-
lation of Ser32-phosphorylated IκB-α in a concentration-dependent
manner (Fig. 4B). Treatment with insulin was thus shown to promote
IκB-α phosphorylation, thus accounting for NF-κB translocation into
the nucleus.Fig. 3. The effect of insulin on NF-κB activation in TNF-α-stimulated endothelial cells.
A: Electrophoreticmobility gel shift assay (EMSA), showing the effect of TNF-α±insulin on
NF-κB activation. EMSAwas performedbymixing the 32P-oligonucleotide encoding for the
NF-κB consensus sequence in the VCAM-1 promoter with nuclear proteins from HUVEC
treatedwith insulin (10−9–10−8mol/L) for 16hbefore TNF-α stimulation (1ng/mLadded to
HUVEC during the last 15 min of insulin treatment). Electrophoretic runs with nuclear
protein extracts from HUVEC treated with insulin+TNF-α 1 ng/mL or TNF-α alone are
shown in lanes 3–4 and 2 respectively. The electrophoretic run with unlabeled (cold)
oligonucleotide is shown in lane 5, while the run with nuclear protein extracts from
unstimulated HUVEC is shown in lane 1. B: The densitometry plot of the NF-κB band from
the autoradiogram. Results are representative of 3 separate experiments.
Fig. 4. Effects of the proteasome inhibitor lactacystin on VCAM-1 surface expression
induced by TNF-α in the presence or absence of insulin in endothelial cells, and effects of
TNF-α, with or without insulin, on the phosphorylated and total cellular levels of IκB-α.
Panels A and B: VCAM-1 surface expression, at EIA, in cells pretreated with lactacystin
(10 μmol/L for 30min), and then co-incubatedwith insulin (10−9 to 10−7mol/L) and TNF-α
for 16 h. ⁎pb0.05 vs non-insulin-stimulated control; #pb0.001 vs non-lactacystin treated
cells. Results are expressed as mU of optical density, and each concentration point is the
mean±S.D. from 3 experiments, each consisting of 8 replicates per condition. B: Immuno-
blottings with antibodies against Ser32-phosphorylated (upper panels) or non-phosphory-
lated IκB-α (bottom panels) in total proteins extracted fromHUVEC incubatedwith insulin
(10−9–10−7 mol/L) for 16 h, with (B) subsequent incubation with 0.1 ng/mL TNF-α for
15 min.We next examined the effect of the proteasome inhibitor lactacystin
(10 μmol/L) on insulin-induced VCAM-1 expression in the presence of
TNF-α. In the absence of any cytotoxicity, treatment of HUVEC with
lactacystin signiﬁcantly decreased TNF-α-induced VCAM-1 expression
(⁎pb0.05 vs TNF-treated cells, Fig. 4A), and this effect was further
potentiated in HUVEC co-treated with insulin and TNF-α (# pb0.001,
Fig. 4A). Taken together, these results demonstrate that NF-κB plays a
key role in mediating the pro-inﬂammatory effects of high insulin in
cytokine-induced human endothelial cells.
4. Discussion
We had previously demonstrated that insulin, at pathophysiologi-
cally relevant concentrations, exerts pro-inﬂammatory and pro-athero-
genic effects on endothelial cells by enhancing VCAM-1 expression and
monocyte-endothelial interactions [18,19]. The present ﬁndings now
(a) demonstrate the ability of insulin to act in concert with other pro-
inﬂammatory stimuli in enhancing the surface expressionof VCAM-1 on
endothelial cells and (b) provide a mechanistic explanation of the
observed effects. This is – to the best of our knowledge – the ﬁrst report
showing the additive effects of insulin and pro-inﬂammatory cytokines
on endothelial activation.
We used insulin concentrations between 10−9 and 10−7 mol/L, in
the range of binding and activation of insulin receptors in endothelial
cells [28]. Such concentrations, equivalent to 139–13,900 μU/mL, span
from pathophysiological to pharmacological levels of insulinemia.
Concentrations of 10−9 and 10−8 mol/L are indeed attainable in fasting
and post-prandial states of individuals with insulin resistance [29],
indicating the plausibility, with all the limitations of extrapolating
from in vitro ﬁndings, that these observations are applicable to in vivo
settings where hyperinsulinemia occurs.
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synergize in the upregulation of endothelial adhesion molecule ex-
pression during immune and inﬂammatory processes [30]. TNF-α has
been shown to be a mediator of insulin resistance in infection, tumor
cachexia and obesity [4,5]. Indeed TNF-α is known to impair tyrosine
kinase activity of both insulin receptor (IR) and IR substrate-1 (IRS-1),
with subsequent blocking of the IRS-1/phosphatidyl inositol(PI)-3
kinase association, through multi-site phosphorylations of serine/
threonine residues as a consequence of the activation of multiple
serine/threonine protein kinases or the inactivation of serine/threo-
nine phosphatases [4]. In addition, TNF-α, through serine/threonine
or tyrosine phosphorylations, has been shown to enhance the activity
of mitogen-activated protein (MAP) kinases [31], particularly p38MAP
kinase [32]. Furthermore, insulin has been recently shown to sti-
mulate TNF-α production in macrophages, by regulating the expres-
sion of TNF-αmRNA through the ERK signaling pathway [17]. All these
interactions, together with the known ability of these primary cyto-
kines to activate the gene expression of adhesion molecules through
NF-κB activation, provide ample biological rationale for the observed
at-least-additive interaction between insulin and inﬂammatory cyto-
kines or LPS, here for the ﬁrst time formally demonstrated. The ability
of insulin, alone or in combination with low concentrations of TNF-α,
to promote VCAM-1 expression in our system appears related, at least
in part, to the ability of insulin to increase steady-state levels of mRNA,
in turn due to insulin ability to activate transcription factors
traditionally implicated in VCAM-1 transactivation, such as NF-κB.
In conclusion, mimicking hyperinsulinemia and the simultaneous
exposure to inﬂammatory mediators in vitro we have shown here the
promotion of pro-atherogenic actions of insulin in endothelial cells.
Favoring the pro-atherogenic properties of inﬂammatory cytokines on
the endothelium may represent a major pathogenetic mechanism
involved in increased atherogenesis and the promotion of vascular
disease in patients with type 2 diabetes and the metabolic syndrome.
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